CymaBay Therapeutics (NASDAQ: CBAY) announced new data from a Phase 2 study of seladelpar for treating primary biliary cholangitis (PBC). The study showed significant improvement in pruritus, with 58% and 93% of patients experiencing at least a 20-point decrease in itching after one year with the 5/10 mg and 10 mg doses, respectively. Additionally, 81% and 78% of patients reported improved sleep disturbances associated with itch. Seladelpar, a selective PPARδ agonist, is on clinical hold pending FDA review. The findings were presented at Digestive Disease Week 2020.
CymaBay Therapeutics (Nasdaq: CBAY) is hosting its 2020 Annual Meeting of Stockholders virtually on June 23, 2020, at 10:00 a.m. Pacific Time. This decision results from public health concerns related to the COVID-19 pandemic. Stockholders can participate via live audio webcast, ensuring equal opportunity for interaction. Voting and question submissions will be available electronically using a 16-digit control number. The company encourages early voting and proxy submissions to ensure participation.
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced a conference call on May 11, 2020, at 4:30 p.m. ET to discuss its financial results for Q1 2020, which ended on March 31, 2020. The call will provide an update on the company's business as it focuses on developing therapies for liver and other chronic diseases.
Investors can access the call by dialing specific numbers provided or through the company's website for a live and archived audio webcast.